
    terminated due to results of interim analysis
  
['multiple myeloma']
['granix', 'high dose melphalan (hdr)']

        Inclusion Criteria:

          -  Symptomatic multiple myeloma requiring treatment

          -  Received at least two cycles of any regimen as initial systemic therapy for multiple
             myeloma and are within 2-12 months of the first dose of initial therapy

          -  At least 18 years of age

          -  Adequate autologous stem cell collection, defined as an unmanipulated, cryopreserved,
             peripheral blood stem cell collection containing at least 2 × 10^6 CD34+ cells/kg
             based on patient body weight.

          -  Adequate organ function as measured by:

               -  Cardiac function: Left ventricular ejection fraction at rest ≥40%

               -  Hepatic function: Bilirubin ≤2 × ULN and aspartate amino transferase/alanine
                  amino transferase (AST/ALT) ≤3 × ULN

               -  Renal function: Creatinine clearance ≥40 mL/minute (measured or
                  calculated/estimated)

               -  Pulmonary function: Carbon monoxide diffusing capacity (DLCO; corrected for
                  hemoglobin [Hgb]), forced expiratory volume in 1 second (FEV1), forced expiratory
                  vital capacity (FVC) ≥50% of predicted value

               -  Oxygen saturation ≥92% on room air

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.

          -  Able to understand and willing to sign an IRB-approved written informed consent
             document

        Exclusion Criteria:

          -  Evidence of multiple myeloma disease progression (as defined by IMWG) any time prior
             to ASCT

          -  Prior stem cell transplant (autologous or allogeneic)

          -  Smoldering MM not requiring therapy

          -  Plasma cell leukemia

          -  Systemic amyloid light chain amyloidosis

          -  Active bacterial, viral, or fungal infection

          -  Seropositive for human immunodeficiency virus (HIV)

          -  Known, active hepatitis A, B, or C Infection

          -  Pregnant or breastfeeding.

          -  Receiving other concurrent anticancer therapy (including chemotherapy, radiation,
             hormonal treatment, or immunotherapy, but excluding corticosteroids) within 7 days
             prior to the ASCT or planning to receive any of these treatments prior to the last
             study visit on Day +100.

          -  Hypersensitive or intolerant to any component of the study drug(s) formulation

          -  Receiving growth factors (filgrastim, XM02-filgrastim, peg-filgrastim, plerixafor,
             etc) or undergoing apheresis < 14 days prior to the start of treatment on protocol
             (Day -7).
      